Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Corporate Update
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will report its Q2 2022 financial and operational results after U.S. markets close on August 9, 2022. The conference call and webcast will be held at 4:30 PM Eastern Time the same day, providing updates on the company’s performance in developing therapeutics for neurological disorders, focusing on epilepsy. Investors can access the live webcast on Xenon's website, with a replay available afterward. The announcement underscores Xenon's commitment to addressing high unmet medical needs in neurology.
- Focus on developing innovative therapeutics for neurological disorders.
- Emphasis on addressing high unmet medical needs, particularly in epilepsy.
- None.
BURNABY, British Columbia, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, August 9, 2022.
Conference Call/Webcast Information:
| Date: | Tuesday, August 9, 2022 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-In Number: | 1-800-715-9871 |
| International Dial-In: | 1-646-307-1963 |
| Conference ID: | 6560707 |
The webcast will also be broadcast live on the “Investors” section of Xenon's website at investor.xenon-pharma.com and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
FAQ
When will Xenon Pharmaceuticals report its Q2 2022 financial results?
What time is the Xenon Pharmaceuticals conference call?
How can I access the Xenon Pharmaceuticals webcast?
What is the focus of Xenon Pharmaceuticals?
What is the ticker symbol for Xenon Pharmaceuticals?
